Haematologica
HAEMATOL/2018/204792
Version 3

Phase 1/2 trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms

Anna B. Halpern, Megan Othus, Emily M. Huebner, Bart L. Scott, Paul C. Hendrie, Mary-Elizabeth M. Percival, Pamela S. Becker, Heather A. Smith, Vivian G. Oehler, Johnnie J. Orozco, Ryan D. Cassaday, Kelda M. Gardner, Tara L. Chen, Sarah A. Buckley, Kaysey F. Orlowski, Asma Anwar, Elihu H. Estey, and Roland B. Walter

Disclosures: The authors declare no competing financial interests

Contributions: A.B.H led the clinical trial, contributed patients, was responsible for adverse event assessment/data collection and preparation of the dataset used for statistical analyses, interpreted data, and drafted the manuscript. M.O. performed all statistical analyses, interpreted data, and critically revised the manuscript. E.M.H., S.A.B., K.F.O., and A.A. contributed to adverse event assessment/data collection and critically revised the manuscript. B.L.S., P.C.H., M.-E.M.P., P.S.B., H.A.S., V.G.O., J.J.O., R.D.C., and K.M.G. contributed patients and critically revised the manuscript. T.L.C. was responsible for the design of the pharmacy aspects of the clinical trial. E.H.E. was responsible for the conception and design of the clinical trial, interpreted data, and critically revised the manuscript. R.B.W. was responsible for the conception and design of the clinical trial, led the clinical trial, interpreted data, and drafted the manuscript. A.B.H. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.